p38 MAPK-dependent eNOS upregulation is critical for 17beta-estradiol-mediated cardioprotection following trauma-hemorrhage. 2008

Wen-Hong Kan, and Jun-Te Hsu, and Zheng-Feng Ba, and Martin G Schwacha, and Jianguo Chen, and Mashkoor A Choudhry, and Kirby I Bland, and Irshad H Chaudry
Center for Surgical Research and Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Studies have shown that p38 MAPK and nitric oxide (NO), generated by endothelial NO synthase (eNOS), play key roles under physiological and pathophysiological conditions. Although administration of 17beta-estradiol (E2) protects cardiovascular injury from trauma-hemorrhage, the mechanism by which E2 produces those effects remains unknown. Our objective was to determine whether the E2-mediated activation of myocardial p38 MAPK and subsequent eNOS expression/phosphorylation would protect the heart following trauma-hemorrhage. To study this, male Sprague-Dawley rats underwent soft-tissue trauma (midline laparatomy) and hemorrhagic shock (mean blood pressure 35-40 mmHg for 90 min), followed by fluid resuscitation. Animals were pretreated with specific p38 MAPK inhibitor SB-203580 (SB; 2 mg/kg), and nonselective NO synthase inhibitor NG-nitro-l-arginine methyl ester (l-NAME; 30 mg/kg) 30 min before vehicle (cyclodextrin) or E2 (100 microg/kg) treatment, followed by resuscitation, and were killed 2 h thereafter. Cardiovascular performance and other parameters were measured. E2 administration following trauma-hemorrhage increased cardiac p38 MAPK activity, eNOS expression and phosphorylation at Ser(1177), and nitrate/nitrite levels in plasma and heart tissues; these were associated with normalized cardiac performance, which was reversed by SB administration. In addition, E2 also prevented trauma-hemorrhage-induced increase in cytokines (IL-6 and TNF-alpha), chemokines (macrophage inflammatory protein-2 and cytokine-induced neutrophil chemoattractant-1), and ICAM-1, which was reversed by l-NAME administration. Administration of E2 following trauma-hemorrhage attenuated cardiac tissue injury markers, myeloperoxidase activity, and nitrotyrosine level, which were reversed by treatment with SB and l-NAME. The salutary effects of E2 on cardiac functions and tissue protection following trauma-hemorrhage are mediated, in part, through activation of p38 MAPK and subsequent eNOS expression and phosphorylation.

UI MeSH Term Description Entries
D007093 Imidazoles Compounds containing 1,3-diazole, a five membered aromatic ring containing two nitrogen atoms separated by one of the carbons. Chemically reduced ones include IMIDAZOLINES and IMIDAZOLIDINES. Distinguish from 1,2-diazole (PYRAZOLES).
D008297 Male Males
D009195 Peroxidase A hemeprotein from leukocytes. Deficiency of this enzyme leads to a hereditary disorder coupled with disseminated moniliasis. It catalyzes the conversion of a donor and peroxide to an oxidized donor and water. EC 1.11.1.7. Myeloperoxidase,Hemi-Myeloperoxidase,Hemi Myeloperoxidase
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D009566 Nitrates Inorganic or organic salts and esters of nitric acid. These compounds contain the NO3- radical. Nitrate
D009573 Nitrites Salts of nitrous acid or compounds containing the group NO2-. The inorganic nitrites of the type MNO2 (where M Nitrite
D010766 Phosphorylation The introduction of a phosphoryl group into a compound through the formation of an ester bond between the compound and a phosphorus moiety. Phosphorylations
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002147 Calmodulin A heat-stable, low-molecular-weight activator protein found mainly in the brain and heart. The binding of calcium ions to this protein allows this protein to bind to cyclic nucleotide phosphodiesterases and to adenyl cyclase with subsequent activation. Thereby this protein modulates cyclic AMP and cyclic GMP levels. Calcium-Dependent Activator Protein,Calcium-Dependent Regulator,Bovine Activator Protein,Cyclic AMP-Phosphodiesterase Activator,Phosphodiesterase Activating Factor,Phosphodiesterase Activator Protein,Phosphodiesterase Protein Activator,Regulator, Calcium-Dependent,AMP-Phosphodiesterase Activator, Cyclic,Activating Factor, Phosphodiesterase,Activator Protein, Bovine,Activator Protein, Calcium-Dependent,Activator Protein, Phosphodiesterase,Activator, Cyclic AMP-Phosphodiesterase,Activator, Phosphodiesterase Protein,Calcium Dependent Activator Protein,Calcium Dependent Regulator,Cyclic AMP Phosphodiesterase Activator,Factor, Phosphodiesterase Activating,Protein Activator, Phosphodiesterase,Protein, Bovine Activator,Protein, Calcium-Dependent Activator,Protein, Phosphodiesterase Activator,Regulator, Calcium Dependent
D002316 Cardiotonic Agents Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). Cardiac Stimulant,Cardiac Stimulants,Cardioprotective Agent,Cardioprotective Agents,Cardiotonic,Cardiotonic Agent,Cardiotonic Drug,Inotropic Agents, Positive Cardiac,Myocardial Stimulant,Myocardial Stimulants,Cardiotonic Drugs,Cardiotonics,Agent, Cardioprotective,Agent, Cardiotonic,Drug, Cardiotonic,Stimulant, Cardiac,Stimulant, Myocardial

Related Publications

Wen-Hong Kan, and Jun-Te Hsu, and Zheng-Feng Ba, and Martin G Schwacha, and Jianguo Chen, and Mashkoor A Choudhry, and Kirby I Bland, and Irshad H Chaudry
March 2007, Molecular immunology,
Wen-Hong Kan, and Jun-Te Hsu, and Zheng-Feng Ba, and Martin G Schwacha, and Jianguo Chen, and Mashkoor A Choudhry, and Kirby I Bland, and Irshad H Chaudry
December 2003, Journal of applied physiology (Bethesda, Md. : 1985),
Wen-Hong Kan, and Jun-Te Hsu, and Zheng-Feng Ba, and Martin G Schwacha, and Jianguo Chen, and Mashkoor A Choudhry, and Kirby I Bland, and Irshad H Chaudry
May 2007, Shock (Augusta, Ga.),
Wen-Hong Kan, and Jun-Te Hsu, and Zheng-Feng Ba, and Martin G Schwacha, and Jianguo Chen, and Mashkoor A Choudhry, and Kirby I Bland, and Irshad H Chaudry
February 2007, American journal of physiology. Lung cellular and molecular physiology,
Wen-Hong Kan, and Jun-Te Hsu, and Zheng-Feng Ba, and Martin G Schwacha, and Jianguo Chen, and Mashkoor A Choudhry, and Kirby I Bland, and Irshad H Chaudry
January 2007, American journal of physiology. Heart and circulatory physiology,
Wen-Hong Kan, and Jun-Te Hsu, and Zheng-Feng Ba, and Martin G Schwacha, and Jianguo Chen, and Mashkoor A Choudhry, and Kirby I Bland, and Irshad H Chaudry
May 2011, Shock (Augusta, Ga.),
Wen-Hong Kan, and Jun-Te Hsu, and Zheng-Feng Ba, and Martin G Schwacha, and Jianguo Chen, and Mashkoor A Choudhry, and Kirby I Bland, and Irshad H Chaudry
June 2008, American journal of physiology. Regulatory, integrative and comparative physiology,
Wen-Hong Kan, and Jun-Te Hsu, and Zheng-Feng Ba, and Martin G Schwacha, and Jianguo Chen, and Mashkoor A Choudhry, and Kirby I Bland, and Irshad H Chaudry
March 2008, Journal of leukocyte biology,
Wen-Hong Kan, and Jun-Te Hsu, and Zheng-Feng Ba, and Martin G Schwacha, and Jianguo Chen, and Mashkoor A Choudhry, and Kirby I Bland, and Irshad H Chaudry
May 2007, Journal of cellular physiology,
Wen-Hong Kan, and Jun-Te Hsu, and Zheng-Feng Ba, and Martin G Schwacha, and Jianguo Chen, and Mashkoor A Choudhry, and Kirby I Bland, and Irshad H Chaudry
July 2012, The Journal of surgical research,
Copied contents to your clipboard!